Christopher Roland Wellaway

This inventor holds 14 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 6 EPO patents. Top assignees: Glaxosmithkline Intellectual Property (No.2) Limited, Glaxo Group Limited, Glaxosmithkline Intellectual Property Development Limited. Active years: 2013-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christopher Roland Wellaway. Retrieved from https://idiyas.com/inventor/christopher-roland-wellaway

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 2)

% Patents Active = 78.6

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 9.9

ph-index = 3

Forward Citations = 42(Granted Patents)

Company Filing History:

5 out of 95

Glaxosmithkline Intellectual Property (No.2) Limited

Glaxosmithkline Intellectual Property Development Limited

5. 1 out of 834,601

Other

patents

Years Active: 2013-2022

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11478478 - 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors (2022-10-25),

2. 10815218 - Benzoimidazole derivatives as PAD4 inhibitors (2020-10-27),

3. 10583139 - 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors (2020-03-10),

4. 10407407 - Benzoimidazole derivatives as PAD4 inhibitors (2019-09-10),

5. 10059699 - Tetrahydroquinoline derivatives as bromodomain inhibitors (2018-08-28),

6. 10039755 - 2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors (2018-08-07),

7. 10034881 - 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors (2018-07-31),

8. 9833449 - 2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors (2017-12-05),

9. 9670221 - Furopyridines as bromodomain inhibitors (2017-06-06),

10. 9663533 - Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors (2017-05-30),

11. 9637456 - 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors (2017-05-02),

12. 9518054 - 2-(azaindol-2-yl) benz imidazoles as PAD4 inhibitors (2016-12-13),

13. 9127003 - 2-(azaindol-2-yl)benzimidazoles as PAD4 inhibitors (2015-09-08),

14. 8383635 - Chemical compounds (2013-02-26),

Certainly! Here is an article about the inventor Christopher Roland Wellaway:

Title: Innovator Spotlight - Christopher Roland Wellaway

Introduction:

Christopher Roland Wellaway is a distinguished inventor hailing from Stevenage, GB. With a track record of 14 patents under his belt, Wellaway has made significant contributions to the field of pharmaceuticals and biotechnology.

Latest Patents:

Wellaway's recent patents showcase his innovative work in the pharmaceutical realm. His inventions include 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives, which serve as bromodomain inhibitors, opening new possibilities in therapy. Additionally, his Benzoimidazole derivatives act as PAD4 inhibitors, showing promise in treating various disorders such as rheumatoid arthritis, cancer, and asthma.

Career Highlights:

Wellaway has been associated with reputable companies in the pharmaceutical industry, including GlaxoSmithKline Intellectual Property Limited and Glaxo Group Limited. His tenure at these organizations has been marked by groundbreaking research and development in the field of biopharmaceuticals.

Collaborations:

Throughout his career, Wellaway has collaborated with notable professionals in the industry. Working alongside individuals like Stephen John Atkinson and Dominique Amans, he has shared expertise and insights, leading to the development of impactful inventions.

Conclusion:

In conclusion, Christopher Roland Wellaway stands out as a pioneering inventor with a passion for innovation in the pharmaceutical sector. His trailblazing work in developing novel compounds and inhibitors underscores his commitment to advancing healthcare and improving treatment options for various medical conditions. Wellaway's contributions continue to leave a lasting impact on the field of biopharmaceuticals and beyond.

Profile summary based on public USPTO records.